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Abstract
Background: Pancreatic cancer has the worst survival rate among all cancers. Almost 70% of patients were 
diagnosed at Stage IV. 
Aim: This study aimed to investigate the symptoms associated with the diagnoses of pancreatic ductal 
adenocarcinoma (PDAC) and neuroendocrine neoplasms (PNEN), comparatively characterise the 
symptomatology between the two tumour types to inform earlier diagnosis.
Design and Setting: A nested case-control study was conducted using data from the QResearch database. 
Patients aged ≥25 years and diagnosed with PDAC or PNEN during 2000-2019 were the cases. Up to 10 
controls from the same general practice were matched with each case by age, sex, and calendar year using 
incidence density sampling.
Methods: Conditional logistic regression was used to investigate the association between the forty-two 
shortlisted symptoms and the diagnoses of PDAC/PNEN in different timeframes relative to the index date, 
adjusting for patients’ sociodemographic characteristics, lifestyle, and relevant comorbidities. 
Results: There were 23,640 patients diagnosed with PDAC and 596 with PNEN. Twenty-three symptoms 
were significantly associated with PDAC, and nine symptoms with PNEN. Jaundice and gastrointestinal 
bleeding were the two alarm symptoms for both tumours. Thirst and dark urine were the two new 
identified symptoms for PDAC. The risk of unintentional weight loss may be longer than two years before 
the diagnosis of PNEN.
Conclusion: PDAC and PNEN have overlapping symptom profiles. The QCancer (Pancreas) risk prediction 
model could be updated by including the newly identified symptoms and comorbidities, which could help 
GP identify high-risk patients for timely investigation in primary care.
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How this fits in
This is the largest population-based study of its kind, systematically examining the symptomology of 
pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine neoplasms (PNEN), and 
quantifying the association of 42 potential symptoms in different time windows relative to the date of 
diagnosis. This study confirmed several symptoms as risk factors for PDAC reported in previous UK studies 
with much smaller sample sizes. A deeper understanding of symptoms associated with PNEN is gained 
beyond archetypal but rare symptoms of hormone hypersecretion.
Considering most symptoms associated with pancreatic cancer are non-specific and not qualified for 
urgent referral for investigation (two-week wait) in the current NICE guideline, general practitioners (GP) 
should be vigilant of patients presenting with several concurrent non-specific symptoms and make proper 
safety-netting strategies. GP should also increase the awareness of the risk of pancreatic cancer among 
people with comorbidities, and be careful not to attribute potential symptoms of pancreatic cancer to 
patients with existing health conditions.
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Introduction
Pancreatic cancer is the tenth most common cancer in incidence but represents the fifth most common 
cause of cancer death in the UK. Pancreatic cancer is very aggressive and has the worst survival rate among 
all types of cancer (1). Tumours arising from the pancreas can be classified as exocrine (approximately 
95%) or neuroendocrine (≤5%) neoplasms (2), known as pancreatic ductal adenocarcinoma (PDAC) and 
pancreatic neuroendocrine neoplasms (PNEN) (3), respectively. Although there are differences in tumour 
pathobiology and treatment strategies between PDAC and PNEN, the two tumour types share a proclivity 
to metastasis (4-6). More favourable outcomes were observed in earlier stages at diagnosis (7). 
In the absence of a screening programme for pancreatic cancer in the UK, symptomatic presentation in 
general practice remains a key avenue for earlier diagnosis. However, besides jaundice, current literature 
reporting symptoms associated with pancreatic cancer are vague and non-specific (8, 9). General 
practitioners (GPs) face the challenges of differentiating a potential malignancy from other benign 
diseases when patients present with non-specific symptoms, which could be easily ‘missed’ or delayed 
diagnosis of the tumour. In addition, as a rarer type of cancer, there is still no large scale study 
characterising the symptomatology of PNEN, nor have studies comprehensively compared the 
symptomatology of PDAC with PNEN. Therefore, a better understanding of the symptomatology and the 
timings at which patients present with symptoms could help GPs better manage patients and make clinical 
decisions. Furthermore, such symptoms could be used in social campaigns to increase public awareness 
of pancreatic cancer. 
To address this research gap, we conducted this study with three aims: 1) to explore the symptoms that 
patients presented in primary care in different time windows that may portend the diagnosis of 
PDAC/PNEN; 2) to comparatively characterise the symptomatology of PDAC and PNEN, and 3) to inform 
the update of the QCancer (Pancreas) prediction model (10, 11). The QCancer (Pancreas) score quantifies 
the risk of an incident diagnosis of pancreatic cancer in the next two years, based on an individual patient’s 
characteristics. Such a risk score may help GP make different decisions: a two-week wait referral for 
patients with high-risk, watchful wait and safety-netting for patients with low risk.
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Methods
Study design and setting 
This is a nested case-control study using the QResearch database (Version 44), an extensive validated 
anonymised primary care database comprising records of over 35 million patients registered in 
approximately 1500 GP surgeries spread throughout the UK using the EMIS System since 1989. Population 
in the QResearch database is representative of the UK population. Patients’ records have been linked with 
cancer registries, ONS mortality records, and hospital episode statistics. The cancer registration data 
include information on the date of diagnosis, type and location of the tumour, morphology, grade and 
stage, and treatment. 
Study population 
An open cohort of patients aged ≥25 years and registered in the QResearch database between 1 January 
2000 and 31 December 2019 was the eligible study population. Patients with an existing diagnosis of any 
type of pancreatic cancer before the entry date were excluded. The entry date to the cohort was the latest 
of the patient’s 25th birthday, the date of patients registered with the practice plus one year, the date on 
which the practice computer system was installed plus one year, or the beginning of the study period. The 
right censor date was the earliest date of the following: the date of pancreatic cancer diagnosis, the date 
of death, the date leaving the practice, or the study end date. Person years were calculated between the 
study entry date and the right censor date.
Identification of cases and controls
Cases were patients in the study cohort with an incident diagnosis of PDAC/PNEN, recorded in one or more 
of the four linked sources – GP records, HES, cancer registry, or ONS. The index date for cases was the 
earliest date the diagnosis was recorded in any four data sources. Cases were matched with up to 10 
controls in the same practice, age, sex, and calendar year using incidence density sampling (12). Each 
control was allocated an index date, which was the date of diagnosis of their matched case. 
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Candidate symptoms and potential risk factors
A broad list of symptoms potentially associated with PDAC and PNEN is summarised in Box 1. These 
symptoms were identified through literature review (2, 10, 13, 14), information from the leading charities 
such as Cancer Research UK (15) and Pancreatic Cancer UK (16), NICE guidelines – NG12 (17) and NG85 
(18), and patient representatives. All occurrences of symptoms in primary care records were extracted, 
but the analysis was focused on the most recent five years before the index date. In addition, the following 
variables were of research interest and adjusted in the models, including patients’ sociodemographic 
characteristics (ethnicity, socioeconomic deprivation using Townsend quintile), lifestyle factors (smoking 
and drinking statuses, and body mass index (BMI), using most recent available values before the index 
date), and relevant comorbidities that could cause the symptoms, or as potential risk factors for pancreatic 
cancer. 
Statistical analysis
Descriptive statistics were used to summarise the sociodemographic and clinical characteristics of patients 
diagnosed with PDAC and PNEN, and the matched control group. The key clinical characteristics of PDAC 
and PNEN cases were compared.
Exploratory analyses were conducted to investigate the association between the most recent recorded 
symptom relative to the index date in seven different periods and patient groups (case/control) using 
univariable conditional logistic regression. These seven timeframes were <1 month, 1-3 months, 4-6 
months, 7-12 months, 1-2 years, 2-3 years, and 3-5 years before the index date. The purpose of setting 
different timeframes for the same symptoms was to compare how the odds ratio (OR) would change, and 
the implication of timeframes for earlier diagnosis of PDAC and PNEN based on symptomatic presentation.  
Based on the exploratory results and the clinical relevance of timeframes for earlier diagnosis of pancreatic 
cancer, the seven timeframes were narrowed down to the following four in two sets of analysis:
1) Within 3 months for alarm symptoms, or 1 year for other symptoms (denoted as 3M/1Y);
2) Within 6 months for alarm symptoms, or 2 years for other symptoms (6M/2Y)
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Alarm symptoms included jaundice, dysphagia, and gastrointestinal (GI) bleeding. These three symptoms 
were analysed within shorter timeframes (within 3/6 months before the index date), as they are widely 
accepted as ‘red flag’ symptoms and should be promptly investigated in primary care, or referred to 
secondary care. For the other symptoms, the timeframes were longer (within 1 or 2 years before the index 
date), as they are non-specific, probably caused by other benign conditions, and not easily ascribed to an 
underlying tumour. A categorical variable was used to denote whether the patients presented to their GPs 
for each symptom based on the most recent date of presentation, for example, no record of presenting 
with jaundice (reference category), presenting with jaundice within 3 months, or more than 3 months 
before the index date. Symptoms in other timeframes (6 months, 1 or 2 years) were operationalised in 
the same way. 
Due to the large difference in sample sizes, PDAC and PNEN were analysed separately. Five variables 
contained missing data, including ethnicity, Townsend quintile, BMI, smoking and drinking statuses. 
Multiple imputation with chained equations was used to impute missing values for these variables under 
the missing at random assumption. Ten imputations were conducted. Multivariable conditional logistic 
regression models were used to identify symptoms significantly associated with the diagnoses of PDAC 
and PNENs, adjusting for patient characteristics and comorbidities, with Rubin’s rules used to pool the 
parameter estimates across the ten imputed datasets (19). Possible interactions were considered and 
tested in the model. ORs and the 95% confidence intervals (CI) for each symptom were calculated and 
visualised in forest plots. Symptoms with an OR >1.2 at a significance level of P<0.01 for PDAC or PNEN 
were considered clinically and statistically relevant. Sensitivity analyses were conducted in patients (both 
cases and control) with at least three years of electronic health records (EHRs) before the index date. All 
statistical analyses were conducted in Stata 16.1. The reporting of this study followed the 
recommendations of the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) 
statement (20).
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Results
Population characteristics
The open cohort included 15,194,279 patients aged ≥25 years, with a total of 100,290,294 person-years 
of follow-up. 23,640 PDAC and 596 PNEN cases were identified from the cohort. Case ascertainment from 
the linked data sources is in Supplementary Table 1. The age-standardised incidence rate of PDAC was 
23.21 per 100,000 person-years (95% CI 22.91-23.51) and 0.95 per 100,000 person-years for PNEN (95% 
CI: 0.89-1.01). Table 1 summarises the demographic and clinical characteristics of the cases, organised by 
tumour type. The comparison of characteristics between cases and controls (n=230,024) is in Table 2.
Symptoms associated with PDAC and PNEN
Figures 1 presents the significant results of multivariable analyses for PDAC and PNEN for symptoms 
recorded within 3 months (alarm symptoms) or 1 year (non-specific) before the index date, respectively, 
adjusting for patient characteristics and comorbidities. The significant results for symptoms in the 6M/2Y 
timeframe for PDAC and PNEN are in Figure 2 (considering the publication space, we only plotted the 
significant results, but full results are available in Supplementary Tables 2-5). Most results were congruent 
in the two models, although symptoms in a shorter timeframe (3M/1Y) generally had higher ORs than 
those in a longer period (6M/2Y) and had wider confidence intervals. In addition, symptoms within the 
cut-off periods (e.g. 3/6 months or 1/2 years) were statistically significant. For symptoms longer than the 
cut-off periods, there were two main patterns: either the symptoms became non-significant, or the 
direction of OR in the symptoms reversed (from >1 to <1, significantly higher odds in control), which meant 
the controls were more likely to consult with those (non-specific) symptoms after the cut-off periods. 
Noticeably, the effect of weight loss may be longer than 2 years before the diagnosis of PNEN. Interaction 
terms were tested. However, they were not in the final model because including interaction terms 
increased the number of parameters that need to be estimated. The model was unable to converge, 
especially for PNEN with a small sample size.
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Jaundice had the highest adjusted OR in both PDAC and PNEN. Symptoms associated with PNEN were a 
subset of symptoms associated with PDAC, but the strength of ORs among the significant symptoms may 
not be the same in PDAC and PNEN. Nine symptoms were significantly associated with the diagnosis of 
PNEN in the timeframe of 3M/1Y, including jaundice, GI bleeding, diarrhoea, bowel change, vomiting, 
indigestion, abdominal mass, abdominal pain, and weight loss. The additional significant symptoms 
associated with PDAC included constipation, steatorrhea, abdominal distension, nausea, flatulence, 
heartburn, fever, tiredness, appetite loss, itching, back pain, thirst, and dark urine. 
Other risk factors
Compared with white ethnicity, Indian, Bangladeshi, other Asian (not including Chinese) were less likely 
to develop PDAC (OR<1). Smoking and drinking were the risk factors for PDAC. As to comorbidities, type 2 
diabetes mellitus (T2DM), venous thromboembolism, Cushing’s syndrome, pancreatic cysts, significantly 
increased the risks of PDAC and PNEN. Acute pancreatitis, cholangitis, family history of GI cancer, and type 
1 diabetes were significant risk factors for PDAC, but not for PNEN.
Sensitivity analysis
About 26% of patients (65,884 out of 254,260, including cases and controls) were excluded from sensitivity 
analysis. By comparing the results from the main analysis, the conclusion of symptoms in the sensitivity 
analysis did not change, although there were some changes in OR. Complete results of sensitivity analyses 
are available in Supplementary Tables 6-9.
Discussion
Summary
24,236 patients diagnosed with pancreatic cancer during 2000-2019 were identified from the QResearch 
database. Nine symptoms were significantly associated with the diagnosis of PNEN, which is a subset of 
23 significant symptoms for PDAC. A shorter timeframe (3 months for alarm symptoms and 1 year for non-
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specific symptoms) was considered better than a longer one (6M/2Y) for earlier cancer diagnosis, as cases 
had higher odds of presenting symptoms in the 3M/1Y timeframe. Jaundice had the highest adjusted OR 
in both PDAC and PNEN. Thirst and dark urine were the two newly identified symptoms associated with 
PDAC, not previously reported in other studies. Thirst could be a symptom explained by T2DM, which is 
associated with pancreatic cancer. Dark urine could be caused by progressing liver dysfunction, or the 
manifestation of biliary duct obstruction. All the findings in this study are summarised in Table 3. 
Strengths and limitations
The QResearch database provides rich data for this study, which is by far the largest study of its kind. The 
representative patient population makes the study findings more able to generalise to a broader UK 
population. The use of EHRs avoids selection, recall, and responder biases from survey, also benefits from 
the accuracy of coding and data completeness in the UK general practice. We explored the effects of 
symptoms in seven timeframes first, and then narrowed down to 3M/1Y and 6M/2Y before the index date.  
We did not mix symptoms recorded longer than the timeframes (>3M/1Y, >6M/2Y) with no symptom 
recorded together, which provided new information about the symptoms beyond the cut-off periods in 
cases and controls. Although symptoms were the focus of this study, we took account of, included, and 
adjusted for the background risk factors and relevant comorbidities in the model, which is another 
strength. We conducted the study as transparently and thoroughly as possible. The research protocol has 
been published on the QResearch website. The reporting of this article complies with the STROBE 
statement. 
Information bias in EHRs is the first limitation. We could not evaluate how accurate the information was 
recorded across practices. The recording habit may have a considerable difference among GPs. We 
mitigated the heterogeneity of recording habits by using all possible Read codes for each variable. Due to 
the small sample size in PNEN cases, it is possible that we could not capture the full burden of symptoms 
in PNEN. Therefore, we could not discern whether a lower number of significant symptoms for PNEN is a 
lack of statistical power, or PNEN has truly less prominent symptomatology, or both. We planned to 
explore whether there was any symptom associated with early/late stages at diagnosis in PDAC and PNEN. 
Unfortunately, the large amount of missing data in cancer staging (Supplementary Table 10) did not allow 
us to conduct such an analysis. 
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Comparison with existing literature
The current study has some improvements from our previous QCancer (Pancreas) prediction model (10), 
including a longer study period, a larger sample size of incident cases, more symptoms examined, and the 
exploration of PNEN, which resulted in additional thirteen significant symptoms identified from this study. 
Some UK studies examined the symptomatology of PDAC in primary care settings, with a similar study 
design (matched case-control study) and statistical method (conditional logistic regression), using the 
GPRD (21) and the Health Improvement Network (THIN) (22) databases. The findings in this study are 
generally consistent with the two publications. No studies have systematically and robustly evaluated the 
symptomatology of PNEN in primary care. Patients with PNEN (n=64) reported their symptoms in a 
voluntary, internet-based survey. Given the small sample size and potential recall bias in that study (23), 
we believe our population-based approach offers a more robust and generalisable insight of the PNEN 
symptomatology. Older age, smoking, excess alcohol intake, chronic pancreatitis, and T2DM are common 
risk factors for pancreatic cancer (24-28). The findings are the same here. 
Implications for practice and research
Most symptoms identified in this study do not qualify for a rapid referral in the current NICE guideline for 
suspected (pancreatic) cancer pathway referral [NG12](17). GPs should be vigilant to patients presenting 
with alarm symptoms and non-specific but concerning symptoms, especially when patients have existing 
comorbidities. Public and patient engagement events could raise public awareness of the symptoms of 
pancreatic cancer, which may help patients see their GPs more promptly when noticing bodily changes.
Based on the study findings, we can update the QCancer (Pancreas) prediction model (10) and develop a 
new model for PNEN. It is also possible to quantify the risk of patients presenting with several concurrent 
non-specific symptoms, and the predictive values of such symptom combinations. It would be interesting 
to further understand how GPs managed and investigated patients presented with different symptom 
combinations, and the association with the route to diagnosis and cancer stage. In addition, there is an 
ongoing project in our team, investigating diabetes as a risk pathway towards pancreatic cancer 




Early diagnosis of pancreatic cancer from primary care is still challenging, due to the non-specific 
symptoms. This study identified 23 symptoms associated with the diagnosis of PDAC and nine symptoms 
for PNEN. Risk prediction models incorporating comprehensive symptomatology would help identify 
patients with a high risk of developing pancreatic tumours from primary care. Patients could benefit from 
an earlier cancer diagnosis and better survival outcomes, which can also save costs for the NHS.
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Box 1 – List of 42 candidate symptoms to be examined in this study
 Symptoms in the QCancer (Pancreas) model: abdominal distension (women only), abdominal 
pain, appetite loss, change in bowel habit, constipation (men only), dysphagia (men only), 
haematemesis, indigestion, weight loss
 Symptoms from the literature: back pain, bloating, diarrhoea, fever/shivering, jaundice, 
itching/pruritus, nausea, steatorrhoea, vomiting
 Other potential symptoms to be examined the association with the diagnosis of PDAC/PNEN: 
abdominal mass, gastrointestinal bleeding, rectal bleeding, heartburn/gastro-oesophageal reflux 
(GOR), food regurgitation, flatulence, faecal urgency, dark urine, dry mouth, cracked lips, thirst, 
loss of taste, night sweats, flushes, rash, paleness, oedema, tiredness, appetite increase, weight 
gain, bad breath, bruising, sore lips, hypersomnia
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Age at diagnosis Age bands
25 – 29 years
30 – 39 years 
40 – 49 years
50 – 59 years
60 – 69 years
70 – 79 years
80+ years 
11           (0.05)
129         (0.55)
666         (2.82)
2,325      (9.84)
5,176      (21.90)
7,717      (32.64)
7,616      (32.32)
<5
25      (4.19)
84      (14.09)
118    (19.80)
177    (29.70)
135    (22.65)










85           (0.36)
5,542     (23.44)
2,442     (10.33)
364        (1.54)
1,125     (4.92)
1,887     (7.98)
12,195   (51.59)
<5
78       (13.09) 
147     (24.66) 
23       (3.86) 
112    (18.79) 
57       (9.56) 








274         (1.16)
769         (3.25)
593         (2.51)
4,016     (16.99)
17,988   (76.09)
62       (10.40)
53       (8.89) 
27       (4.53) 
161     (27.01) 








303       (1.33)
1,683     (7.48)
1,702     (7.52)
49          (0.2)
18,779   (84.19))
230     (38.59)
58       (9.73) 
61       (10.23) 
<5
246     (41.28) 











23,640    (100)
16       (2.68)
271     (45.47)
274     (45.97)
8         (1.34)
23       (3.86)
N/A
Treatment Surgery
          No
          Yes
Chemotherapy 
17,026     (72.02)
6,614       (27.98)
220      (36.91)
376      (63.09)
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          No
          Yes
Radiotherapy
          No
          Yes
Hormone therapy 
          No
          Yes
Other treatment
          No
          Yes
19,402     (82.07)
4,238       (17.93)
23,000     (97.29)
640           (2.71)
22,547     (99.72)
66             (0.28)
19,030     (80.50)
4,610        (19.50)
430      (72.15)
166      (27.85)
557     (93.46)
39        (6.54)
550      (92.28)
46        (7.72)
458      (76.85)
138      (23.15)
Note: PDAC – pancreatic ductal adenocarcinoma, PNEN – pancreatic neuroendocrine neoplasm, N/A – 
not applicable. Rows with counts less than 5 have been suppressed.
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Table 2 – Demographics, lifestyle, and comorbidities in cases and controls
Characteristic Cases with PDAC 
number (col %)




N 23,640 596 230,024
Sex
     Female
     Male
11,705   (49.51)
11,935   (50.49)
294   (49.33)
302   (50.67)
114,429   (49.75)
115,595   (50.25)
Age, Mean (SD), years
Median (IQR)
73.0 (11.5)
74 (66 – 82)
62.3 (13.2)
64 (53 – 72)
72.0 (11.4)
73 (65 – 81)
Ethnicity 
    White
    Indian
    Pakistani
    Bangladeshi
    Other Asian
    Caribbean
    Black African
    Chinese
    Other 
    Not recorded
12,604  (53.32)
186        (0.79) 
100        (0.42) 
47          (0.20) 
79          (0.33) 
247        (1.04) 
103        (0.44) 
36          (0.15) 
166        (0.70) 
10,072  (42.61)
367    (61.58)
9        (1.51) 
6        (1.01) 
<5 
10      (1.68) 
10      (1.68) 
<5
<5  
12      (2.01) 
173    (29.03)
154,096   (66.69)
2,674        (1.16)
1,150        (0.50)
692           (0.30)
1,223        (0.53)
2,364        (1.03)
1,369        (0.60)
449           (0.20)
1,853        (0.81)
64,154     (27.89)
Townsend quintile
    1 (most affluent)
    2
    3
    4
    5 (most deprived)
    Not recorded
7,054     (29.84)
5,873     (24.84) 
4,758     (20.13) 
3,442     (14.56) 
2,470     (10.45)
43           (0.18)
190    (31.88)
135    (22.65) 
126    (21.14) 
91      (15.27) 
54      (9.06)
0        (0.00)
72,988      (31.73)
58,901      (25.61)
44,581      (19.38)
31,513      (13.70)
21,758      (9.46)
283            (0.12)
Year of index date
    2000-2004
    2005-2009
    2010-2014
    2015-2019
4,358     (18.43)
5,744     (24.30)
6,767     (28.63)
6,771     (28.64)
68      (11.41)
107    (17.95)
225    (37.75)
196    (32.89)
42,402      (18.43)
55,270      (24.03)
66,009      (28.70)
66,343      (28.84)
Smoking status 
    Non-smoker
    Ex-smoker
    Light smoker (<10)
    Moderate smoker (10-19)
    Heavy smoker (20+)
    Not recorded
10,841   (45.86)
7,117     (30.11)
3,047     (12.89)
617        (2.61)
394        (1.67)
1,624     (6.87)
327     (54.87)
170     (28.52)
45       (7.55)
8         (1.34)
7         (1.17)
39       (6.54)
118,626    (51.57)
76,842      (33.41)
16,917      (7.35)
2,908        (1.26)
1,959        (0.85)
12,772      (5.55)
Alcohol consumption
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    Non-drinker 
    Trivial (<1u/day)
    Light (1-2u/day)
    Moderate (3-6u/day)
    Heavy (7-9u/day)
    Very heavy (>9u/day)
    Not recorded 
14,053   (59.45)
3,224     (13.64)
1,480     (6.26)
1,539     (6.51)
142        (0.60)
67          (0.28)
3,135    (13.26)
354     (59.40)
89       (14.93)
41       (6.88)
32       (5.37)
<5
<5
75       (12.58)
139,902    (60.82)
32,028      (13.92)
15,194      (6.61)
14,712      (6.40)
1,173        (0.51)
549           (0.24)
26,466      (11.51)
Comorbidities/previous 
medical history
    Type 1 diabetes
    Type 2 diabetes
    Venous Thrombus Embolism
    Deep vein thrombosis
    Pulmonary embolism
    Acute pancreatitis 
    Chronic pancreatitis 
    Cholangitis 
    Gallstones 
    H. pylori infection
    Family history of GI cancer
    Blood cancer
    Colon cancer 
534        (2.26)
6,581     (27.84)
2,631     (11.13)
1,632     (6.90)
1,320     (5.58)
857         (3.63)
383        (1.62)
477        (2.02)
1,602     (6.78)
996        (4.21)
456        (1.93)
350        (1.48)
371        (1.57)
25       (4.19) 
187    (31.38)
62      (10.40)
35      (5.87)
34      (5.70)
21      (3.52)
6        (1.01)
8        (1.34)
44      (7.38)
37      (6.21)
15      (2.52)
21      (3.52)
10      (1.68)
1,752        (0.76)
38,666      (16.81)
12,565      (5.46)
8,246        (3.58)
5,640        (2.45)
2,208        (0.96)
409           (0.18)
703           (0.31)
12,378      (5.38)
8,359        (3.63)
4,074        (1.77)
4,123        (1.79)
3,829        (1.66)
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Table 3 – Summary of patient and clinical characteristics significantly associated 
with the diagnosis of PDAC and PNEN
PDAC PNEN
Demographics Reduced risks in Indian, Bangladeshi, Other Asian 
(not including Chinese) compared with white 
(OR<1)
Lifestyle BMI (OR<1)
All smoking categories associated with increased 
risks compared with non-smokers




GI bleeding, Jaundice, Dysphagia (3) GI bleeding, jaundice (2)
Symptoms 
(within 1 year)
Diarrhoea, bowel change, vomiting, indigestion, 
abdominal mass, abdominal pain, weight loss (7)
Constipation, steatorrhea, abdominal distension, 
nausea, flatulence, heartburn, fever, tiredness, 
appetite loss, itching, back pain, thirst, dark urine 
(13)
Diarrhoea, bowel change, 
vomiting, indigestion, 
abdominal mass, abdominal 
pain, weight loss (longer than 
2 years) (7)
Comorbidities Type 2 diabetes, Venous Thromboembolism (VTE), 
Cushing's syndrome, pancreatic cyst
acute pancreatitis, cholangitis, family history of GI 
cancer, Type 1 diabetes




Note: PDAC – pancreatic ductal adenocarcinoma; PNEN – pancreatic neuroendocrine neoplasm, those 
coloured in navy are exclusive to PDAC, and those in black are the same symptoms and comorbidities in 
both PDAC and PNEN. 
Page 21 of 21
Figure 1 – Forest plots for multivariable conditional logistic regression after 
multiple imputation (alarm symptoms 3 months before the index date, other 
symptoms 1 year before the index date)
Note: Figure 1-A is for PDAC, and Figure 1-B is for PNEN. Due to a large number of variables in the model, 
only significant results (adjusted odds ratio and 95% CI) were presented in the figures, considering the 
figure size for publication space. Full results of the models are available in Supplementary Tables 2-3.
Figure 2 – Forest plots for multivariable conditional logistic regression after 
multiple imputation (alarm symptoms 6 months before the index date, other 
symptoms 2 years before the index date)
Note: Figure 2-A is for PDAC, and Figure 2-B is for PNEN. Due to a large number of variables in the model, 
only significant results (adjusted odds ratio and 95% CI) were plotted in the figures, considering the figure 
size for publication space. Full results of the models are available in Supplementary Tables 4-5.
 
Figure 1-A. Forest plots for multivariable conditional logistic regression after multiple imputation (PDAC, 
alarm symptoms 3 months before the index date, other symptoms 1 year before the index date) 
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Figure 1-B. Forest plots for multivariable conditional logistic regression after multiple imputation (PNEN, 
alarm symptoms 3 months before the index date, other symptoms 1 year before the index date) 
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Figure 2-A. Forest plots for multivariable conditional logistic regression after multiple imputation (PDAC, 
alarm symptoms 6 months before the index date, other symptoms 2 years before the index date) 
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Figure 2-B. Forest plots for multivariable conditional logistic regression after multiple imputation (PNEN, 
alarm symptoms 6 months before the index date, other symptoms 2 years before the index date) 
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